PROC
Procaps Group S.A.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 1.01
- Prev close
- 1.01
- Mkt cap
- 297.86M
- Vol
- 652.30K
- Avg vol
- 98.16K
- EPS
- 0.51
- P/E
- 5.18
- Div yield
- 0.00%
More statistics
- Low
- 1.01
- High
- 1.01
- Forward P/E
- 9.78
- Beta
- 0.17
- Short ratio
- 1.08
- Inst. own
- 2.93%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 24, 2024
- 50-d avg
- 1.76
- 200-d avg
- 2.30
- 1y target
- 0.00
Key statistics
- Market cap
- 297.86M
- Enterprise value
- 525.07M
- Trailing P/E
- 5.18
- Forward P/E
- 9.78
- PEG ratio
- 0.00
- Price / sales
- 0.72
- Price / book
- 6.77
- EPS (TTM)
- 0.51
- Beta
- 0.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 12.61%
- Revenue (TTM)
- 414.10M
- Revenue growth
- 7.30%
- Free cash flow
- -12.18M
- Total cash
- 17.56M
- Total debt
- 289.92M
- Return on equity
- 373.70%
- Shares outstanding
- 112.82M
- Short % of float
- 0.00%
- 50-day average
- 1.76
- 200-day average
- 2.30
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Dec 24, 2024
Expected Dec 24, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 24, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 1, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 1, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 10, 2024 | Dec 1, 2023 | 0.09 | — | — | — |
| Sep 5, 2023 | Jun 1, 2023 | 0.06 | 0.27 | +0.21 | +350.00% |
| Jun 5, 2023 | Mar 1, 2023 | -0.04 | 0.07 | +0.11 | +275.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 6, 2023 | Brookline Capital | down | Buy | Hold |
About Procaps Group S.A.
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Luxembourg
- Website
- procapsgroup.com
News
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
- Earnings Scheduled For November 14, 2023
- Stocks That Hit 52-Week Lows On Tuesday
- Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
- Earnings Scheduled For November 14, 2022
Your note
Sign in to keep a note on PROC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Exome Asset Management LLC | 0.11% | 126,901 | 335.02K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.03% | 28,938 | 76.40K | Sep 29, 2024 |
| Activest Wealth Management | 0.01% | 10,000 | 26.40K | Sep 29, 2024 |
| Pineridge Advisors LLC | 0.00% | 250 | 660 | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 100 | 264 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 28,938 | 76.40K | Oct 30, 2024 |
| SPDR Portfolio Emerging Markets ETF | 0.00% | 150 | 396 | Sep 29, 2024 |